Yang Hongxia, Qi Guoyan, Dong Huimin, Liu Ze, Ma Mei, Liu Peng
Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, 365 Jianhua Nan Street, Shijiazhuang, Hebei, China.
Hebei Provincial Clinical Research Center for Myasthenia Gravis, Shijiazhuang, China.
Neurol Ther. 2023 Apr;12(2):559-570. doi: 10.1007/s40120-023-00442-3. Epub 2023 Feb 14.
Myasthenia gravis (MG) is a devastating acquired autoimmune disease that can seriously affect the patient's quality of life. It is also a common complication of thymoma. Previous studies have shown that docetaxel alleviates myasthenic symptoms in thymoma with MG (TMG). However, little is known about the protein expression profiles and biomarkers for efficacy after docetaxel treatment.
We recruited 9 healthy controls and 30 patients with TMG for the serum proteomics study with data-independent acquisition (DIA) technology. We further recruited additional 30 patients for the key protein validation by enzyme-linked immunosorbent assay (ELISA).
We identified 43 proteins by trend analysis and analyzed the interaction between these proteins and MG pathogenic proteins from the DisGNET database and the correlation analysis with clinical data of patients with TMG. Among these, KRAS and SELP were screened out and validated. KRAS and SELP increased in patients with TMG and decreased significantly after docetaxel treatment.
Our study revealed that the serum proteins were differentially expressed after docetaxel treatment, suggesting their important role in patients with TMG, as well as the critical role of KRAS and SELP as biomarkers in evaluating the efficacy of docetaxel treatment.
重症肌无力（MG）是一种严重的获得性自身免疫性疾病，会严重影响患者的生活质量。它也是胸腺瘤的常见并发症。既往研究表明，多西他赛可缓解合并MG的胸腺瘤（TMG）患者的肌无力症状。然而，对于多西他赛治疗后的蛋白质表达谱和疗效生物标志物知之甚少。
我们招募了9名健康对照者和30例TMG患者，采用数据非依赖采集（DIA）技术进行血清蛋白质组学研究。我们进一步招募了另外30例患者，通过酶联免疫吸附测定（ELISA）对关键蛋白进行验证。
通过趋势分析鉴定出43种蛋白质，并分析了这些蛋白质与DisGNET数据库中MG致病蛋白之间的相互作用以及与TMG患者临床数据的相关性分析。其中，筛选出KRAS和SELP并进行了验证。TMG患者中KRAS和SELP升高，多西他赛治疗后显著降低。
我们的研究表明，多西他赛治疗后血清蛋白存在差异表达，提示它们在TMG患者中具有重要作用，以及KRAS和SELP作为生物标志物在评估多西他赛治疗疗效中的关键作用。
